Re-irradiation with Radiosurgery for Recurrent Glioblastoma Multiforme
Authors:
Open Access
- 1 June 2011
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 10 (3) , 253-258
Abstract
Local tumor control remains a significant challenge in patients with glioblastoma multiforme (GBM). Despite aggressive radiation therapy approaches, most recurrences are within the high-dose field, limiting the ability to safely re-irradiate recurrence using conventional techniques. Fractionated stereotactic radiosurgery (fSRS) is a technique whose properties make it useful for re-irradiation. We retrospectively reviewed the charts of 14 patients with recurrent GBM treated with salvage radiosurgery. Seven patients were male and seven were female with a median age of 58 (range: 39–76). All patients had prior cranial radiation therapy to a median dose of 60 Gy (58–69). There were 18 lesions treated with a median tumor volume of 6.97 cm3 (0.54–50.0 cm3). fSRS was delivered in 1–3 fractions to a median dose of 24 Gy (18–30 Gy). Median follow-up for the cohort was 8 months (3–22 months). On follow-up MRI, 8 of 18 lesions had a radiographic response. The median time-to-progression following primary irradiation was 8 months (1-28 months) while the median time-to-progression (TTP) following fSRS was 5 months (1–16 months). Median local control following re-irradiation was 5 months and actuarial local control was 21% at 1-year. Overall survival following primary irradiation was 79% at 12 months and 46% at 2 years. Overall survival following re-irradiation was 79% at 6 months and 30% at 1 year. No significant treatment-related toxicity was seen in follow-up. These results indicate that re-irradiation for recurrent GBM using fSRS is well-tolerated and can offer a benefit in terms of progression-free survival (PFS).Keywords
This publication has 25 references indexed in Scilit:
- Reirradiation Tolerance of the Human BrainInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Bevacizumab for recurrent malignant gliomasNeurology, 2008
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- The Role of Chemotherapy in Recurrent Malignant Gliomas: An OverviewCancer Investigation, 1996
- Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomasThe Lancet, 1995
- Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapyEuropean Journal of Cancer, 1994
- Brain TumorsNew England Journal of Medicine, 1991
- Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989
- Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989
- Regrowth Patterns of Glioblastoma Multiforme Related to Planning of Interstitial Brachytherapy Radiation FieldsNeurosurgery, 1988